Raiffeisen Bank International’s Telix Pharmaceuticals TLX Stock Holding History

Raiffeisen Bank International’s Portfolio TLX Stock Details TLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.3M	Sell	115,000 -15,000	-12%	-$153K	0.02%	386
2026 Q1	$1.16M	Buy	+130,000	New	+$990K	0.02%	371

Other funds holding TLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

PIC

Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $15.3B AUM 25.33% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Raiffeisen Bank International's TLX Position: Q2 2026 in Review

Raiffeisen Bank International reduced its Telix Pharmaceuticals (TLX) stake by 12% in Q2 2026, selling an estimated $153K and leaving 115,000 shares worth $1.3M. The position accounts for 0.02% of the portfolio, ranked #386.

Raiffeisen Bank International first reported a position in TLX in Q1 2026 and has held it in 2 quarters since. 61 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

Raiffeisen Bank International held 115,000 shares of Telix Pharmaceuticals worth $1.3M as of Q2 2026.
Raiffeisen Bank International sold 15,000 Telix Pharmaceuticals shares in Q2 2026, an estimated $153K.
Telix Pharmaceuticals made up 0.02% of Raiffeisen Bank International's portfolio in Q2 2026, its #386 holding.
Raiffeisen Bank International first reported a position in Telix Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
61 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Raiffeisen Bank International's 13F filing for Q2 2026, filed 3 Aug 2026.